علاج متلازمة القولون العصبي مع الإمساك (IBS-C)

References

DOI: 10.1053/j.gastro.2022.04.016

• IBS with predominant constipation (IBS-C) is a subtype of IBS that accounts for more than one-third of IBS cases.
• The AGA recommends using linaclotide in patients with IBS-C.
• The AGA suggests using tenapanor in patients with IBS-C.
• The AGA suggests using plecanatide in patients with IBS-C.
• The AGA suggests using tegaserod in patients with IBS-C.
• The AGA suggests using lubiprostone in patients with IBS-C.
• The AGA suggests using PEG laxatives in patients with IBS-C.
• For IBS-C, the FDA responder end point was defined as a participant who reports both a 30% reduction in average daily worst abdominal pain scores and an increase of 1 complete spontaneous bowel movements (CSBMs) per week compared with baseline for 6 of 12 weeks.